Have You Heard The Latest Rumor On Drug Pricing? Orrin Hatch Has
Executive Summary
An exchange during HHS Secretary Burwell’s testimony to the Finance Committee on the fiscal 2017 budget speaks volumes about what is – and is not – on the table for the last year of the Obama Administration.
You may also be interested in...
Medicare Pricing Experiment Won't Extend To Part D, Senate Panel Told
CMS Deputy Administrator Conway's appearance at the Finance Committee prompted questions about a theoretical next demonstration project while members challenged the project currently on the table; Conway suggested some ‘adjustments’ are coming to the proposed Part B demo.
Industry Assesses Threat From Drug-Pricing Debate
Drug pricing and government oversight were raised as critical issues for the industry in panels, presentations and conversations throughout the BIO CEO & Investor conference, with opinions varying on how much of a threat it could be.
CMS-Run Medicaid Purchasing Pools For High-Cost Drugs Floated In Budget
Administration’s proposal to increase Medicaid leverage via more “unified” approach adds another idea to drug-pricing debates, though it would require legislation.